These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37306554)

  • 1. Keeping It in the Family: HER3 as a Target in Brain Metastases.
    Kabraji S; Lin NU
    Clin Cancer Res; 2023 Aug; 29(16):2961-2963. PubMed ID: 37306554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer.
    Tomasich E; Steindl A; Paiato C; Hatziioannou T; Kleinberger M; Berchtold L; Puhr R; Hainfellner JA; Müllauer L; Widhalm G; Eckert F; Bartsch R; Heller G; Preusser M; Berghoff AS
    Clin Cancer Res; 2023 Aug; 29(16):3225-3236. PubMed ID: 37036472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent overexpression of ErbB--receptor family members in brain metastases of non-small cell lung cancer patients.
    Berghoff AS; Magerle M; Ilhan-Mutlu A; Dinhof C; Widhalm G; Dieckman K; Marosi C; Wöhrer A; Hackl M; Zöchbauer-Müller S; Preusser M; Birner P
    APMIS; 2013 Dec; 121(12):1144-52. PubMed ID: 23756255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients.
    Scharpenseel H; Hanssen A; Loges S; Mohme M; Bernreuther C; Peine S; Lamszus K; Goy Y; Petersen C; Westphal M; Glatzel M; Riethdorf S; Pantel K; Wikman H
    Sci Rep; 2019 May; 9(1):7406. PubMed ID: 31092882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
    Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
    J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
    Kodack DP; Askoxylakis V; Ferraro GB; Sheng Q; Badeaux M; Goel S; Qi X; Shankaraiah R; Cao ZA; Ramjiawan RR; Bezwada D; Patel B; Song Y; Costa C; Naxerova K; Wong CSF; Kloepper J; Das R; Tam A; Tanboon J; Duda DG; Miller CR; Siegel MB; Anders CK; Sanders M; Estrada MV; Schlegel R; Arteaga CL; Brachtel E; Huang A; Fukumura D; Engelman JA; Jain RK
    Sci Transl Med; 2017 May; 9(391):. PubMed ID: 28539475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.
    Umelo I; Noeparast A; Chen G; Renard M; Geers C; Vansteenkiste J; Giron P; De Wever O; Teugels E; De Grève J
    Oncotarget; 2016 Jan; 7(3):3068-83. PubMed ID: 26689995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
    Yonesaka K; Tanizaki J; Maenishi O; Haratani K; Kawakami H; Tanaka K; Hayashi H; Sakai K; Chiba Y; Tsuya A; Goto H; Otsuka E; Okida H; Kobayashi M; Yoshimoto R; Funabashi M; Hashimoto Y; Hirotani K; Kagari T; Nishio K; Nakagawa K
    Clin Cancer Res; 2022 Jan; 28(2):390-403. PubMed ID: 34921025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.
    Berghoff AS; Bartsch R; Preusser M; Ricken G; Steger GG; Bago-Horvath Z; Rudas M; Streubel B; Dubsky P; Gnant M; Fitzal F; Zielinski CC; Birner P
    Breast; 2014 Oct; 23(5):637-43. PubMed ID: 25017122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond HER2: Targeting the ErbB receptor family in breast cancer.
    Drago JZ; Ferraro E; Abuhadra N; Modi S
    Cancer Treat Rev; 2022 Sep; 109():102436. PubMed ID: 35870237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-519d targets HER3 and can be used as a potential serum biomarker for non-small cell lung cancer.
    Wang A; Zhang H; Wang J; Zhang S; Xu Z
    Aging (Albany NY); 2020 Mar; 12(6):4866-4878. PubMed ID: 32170048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases.
    Huang RSP; Harries L; Decker B; Hiemenz MC; Murugesan K; Creeden J; Tolba K; Stabile LP; Ramkissoon SH; Burns TF; Ross JS
    Oncologist; 2022 Oct; 27(10):839-848. PubMed ID: 35598205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients.
    Villalva C; Duranton-Tanneur V; Guilloteau K; Burel-Vandenbos F; Wager M; Doyen J; Levillain PM; Fontaine D; Blons H; Pedeutour F; Karayan-Tapon L
    Cancer Med; 2013 Jun; 2(3):296-304. PubMed ID: 23930206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation.
    Improta G; Zupa A; Fillmore H; Deng J; Aieta M; Musto P; Liotta LA; Broaddus W; Petricoin EF; Wulfkuhle JD
    J Proteome Res; 2011 Jul; 10(7):3089-97. PubMed ID: 21574647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of the HER3-targeted antibody patritumab (U3-1287) combined with erlotinib in Japanese patients with non-small cell lung cancer.
    Nishio M; Horiike A; Murakami H; Yamamoto N; Kaneda H; Nakagawa K; Horinouchi H; Nagashima M; Sekiguchi M; Tamura T
    Lung Cancer; 2015 Jun; 88(3):275-81. PubMed ID: 25891541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
    Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
    Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.
    Liu B; Chen D; Chen S; Saber A; Haisma H
    Biochem Pharmacol; 2020 Aug; 178():114095. PubMed ID: 32535106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer.
    Luhtala S; Staff S; Kallioniemi A; Tanner M; Isola J
    BMC Cancer; 2018 Oct; 18(1):1045. PubMed ID: 30367623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER3 and LINC00052 interplay promotes tumor growth in breast cancer.
    Salameh A; Fan X; Choi BK; Zhang S; Zhang N; An Z
    Oncotarget; 2017 Jan; 8(4):6526-6539. PubMed ID: 28036286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.